Keywords
DLBCL relapsed
Chemotherapy
How to Cite
Abstract
Glofitamab is a bispecific CD20xCD3 antibody approved by the FDA and EMA for the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), demonstrating high complete response rates and prolonged survival. Its main adverse event is cytokine release syndrome, usually mild. As monotherapy, in patients with R/R DLBCL it achieves 40% complete response rate, while in combination with chemotherapy (Glofit-GemOx and Glofit-R-ICE), it significantly improves overall survival and response rates. In the first-line setting, its combination with R-CHOP has shown high efficacy in high-risk patients. An emerging challenge is the loss of CD20 after treatment, which may affect its efficacy. Although not yet approved by ANMAT, glofitamab represents a promising option for DLBCL patients in Argentina, especially in the absence of access to CAR-T therapy.
References
Dickinson MJ, Carlo-Stella C, Morschhauser F y col. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 2022;387:2220–2231. https://doi.org/10.1056/NEJMoa2207816
Crombie JL, Graff T, Falchi L y col. Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Blood 2024;143:1565–1575. https://doi.org/10.1182/blood.2023021186
Dickinson MJ, Carlo-Stella C, Morschhauser F y col. Fixed-duration glofitamab monotherapy continues to demonstrate durable responses in patients with relapsed or refractory large B-cell lymphoma: 3-year follow-up from a pivotal Phase II study. Blood 2024;144:865–865.
Abramson JS, Ku M, Hertzberg M y col. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. Lancet 2024;404:1940–1954. ttps://doi.org/10.1016/S0140-6736(23)02779-2
Minard-Colin V, Andión Catalán M, Vinti L y col. Glofitamab in combination with R-ICE chemoimmunotherapy or as monotherapy in children and adolescents with relapsed/refractory B-cell non-Hodgkin lymphoma: Initial safety and efficacy results from the ongoing iMATRIX-GLO study. Blood 2024;144:6483–6483.
García-Sancho AM, Cabero A, Gutiérrez NC. Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: New Approved Options. J Clin Med 2023;13. https://doi.org/10.3390/jcm13010070
Topp MS, Tani M, Dickinson M y col. Glofitamab plus R-CHOP induces high response rates with a manageable safety profile in patients with previously untreated diffuse large B-cell Lymphoma (DLBCL): A 12-month analysis from a phase Ib study. Blood 2023;142:3085–3085.
Minson A, Verner E, Giri P y col. A randomized phase 2, investigator-led trial of glofitamab-R-CHOP or glofitamab-polatuzumab vedotin-R-CHP (COALITION) in younger patients with high burden, highrisk large B-cell lymphoma demonstrates safety, uncompromised chemotherapy intensity, a high rate of durable remissions, and unique FDG-PET response characteristics. Blood 2024;144:582–582.
Advani RH, Dickinson MJ, Fox CP y col. SKYGLO: A global Phase III randomized study evaluating glofitamab plus polatuzumab vedotin + rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola- R-CHP) versus Pola-R-CHP in previously untreated patients with large B-cell lymphoma (LBCL). Blood 2024;144:1718.1–1718.1.
Carlo-Stella C. Relapse after glofitamab, a novel unmet medical need with high rates of CD20 loss. Br J Haematol 2024;205:17–19. https://doi.org/10.1111/bjh.18827
Brooks TR, Zabor EC, Bedelu YB y col. Real-world outcomes with bispecific T-cell engagers (REALBiTE) for relapsed or refractory large B-cell lymphoma: A multi-center, retrospective cohort study. Blood 2024;144:111–111.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar